Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control ; volume:13 ; number:1 ; day:6 ; month:10 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (6.10.2023), 1-15, 12.2023
- Creator
-
Jabir, Majid S.
Al-Shammari, Ahmed M.
Ali, Zainab O.
Albukhaty, Salim
Sulaiman, Ghassan M.
Jawad, Sabrean F.
Hamzah, Sawsan S.
Syed, Asad
Elgorban, Abdallah M.
Eswaramoorthy, Rajalakshmanan
Zaghloul, Nouf S. S.
Al-Dulimi, Ali G.
Najm, Mazin A. A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42299-4
- URN
-
urn:nbn:de:101:1-2024020113462131103572
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jabir, Majid S.
- Al-Shammari, Ahmed M.
- Ali, Zainab O.
- Albukhaty, Salim
- Sulaiman, Ghassan M.
- Jawad, Sabrean F.
- Hamzah, Sawsan S.
- Syed, Asad
- Elgorban, Abdallah M.
- Eswaramoorthy, Rajalakshmanan
- Zaghloul, Nouf S. S.
- Al-Dulimi, Ali G.
- Najm, Mazin A. A.
- SpringerLink (Online service)
Other Objects (12)
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy